ArticleInfectious agents and cancer2025
Parasites' immunomodulators: a breakthrough in immunotherapeutics displaying antineoplastic activity against human colorectal and hepatocellular carcinoma cells.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The dual role of parasites and parasite-derived products in cancer biology: a systematic review ofFrontiers in oncology · 2026Pooled it
- Review
- Glancing at the role of Toxoplasma gondii in neuro-oncology: from risk factor to therapeutic target.Infectious agents and cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex interplay between parasites and cancer is yielding promising advances in the field of cancer therapeutics. This study explored the in vitro anti-cancer potential of parasite immunomodulators (antigens and antibodies) of Schistosoma mansoni, Trichinella spiralis, and Toxoplasma gondii on human HT-29 colorectal and HepG2 hepatocellular carcinoma cells using the MTT assay. Results revealed that those parasites' immunomodulators exhibited antineoplastic activity and demonstrated a statistically significant inhibition of both cancer cell lines' proliferation (P ˂0.05). Notably, Trichinella spiralis antigens and antibodies and anti-Toxoplasma gondii antibodies demonstrated the most statistically significant inhibitory effects on HT-29 colorectal cancer cells (36.65%, 49.9% and 50.43% respectively). For HepG2 hepatocellular carcinoma cells, Trichinella spiralis antigens and antibodies, as well as Toxoplasma gondii antigen, displayed the most statistically significant inhibitory effects (38.27%, 48.25% and 34.68% respectively). Interestingly, parasitic antibodies are particularly noteworthy, exhibiting the most significant inhibitory effects on both cancer cell lines. To the best of our knowledge, this is the first study to demonstrate the antineoplastic activity of parasites' antibodies against human colorectal cancer and hepatocellular carcinoma. These findings could enlighten the path for promising cancer therapeutic candidates. Future research should explore the antineoplastic potential of a broader range of parasites' immunomodulators and identify their mechanisms of action. This could represent a qualitative shift towards the development of innovative cancer therapeutic antibodies and cancer vaccine candidates of parasitic origin for cancer-targeted immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.